Finance

Lists
JBIO:NASDAQ
Jade Biosciences Inc
USD 14,39
+1,70%
(+0,24) 1D
USD 14,39
0,00% (0,00)
After hours
Closed: 9 Okt., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for JBIO...
Open
USD 14,16
High
USD 14,81
Low
USD 14,00
Mkt. cap
915,17 m
Avg. vol.
959,89 k
Volume
735,60 k
52-wk high
USD 27,96
52-wk low
USD 8,36
EPS
-USD 2,31
Beta
1,64
Shares outstanding
63,60 m
No. of employees
55
Open
USD 14,16
High
USD 14,81
Low
USD 14,00
Mkt. cap
915,17 m
Avg. vol.
959,89 k
Volume
735,60 k
52-wk high
USD 27,96
52-wk low
USD 8,36
EPS
-USD 2,31
Beta
1,64
Shares outstanding
63,60 m
No. of employees
55
News stories
From web sources and news partners
About Jade Biosciences Inc
CEO-
Employees55
Founded2024
HeadquartersWaltham, Massachusetts, Verenigde State van Amerika
Sector-
Websitejadebiosciences.com
Analyst ratings
Based on 10 analysts giving stock ratings to JBIO in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for JBIO in the last 3 months.
Highest
Current USD 14,39
USD 77,00 (+435,09%)
Average
USD 50,50 (+250,94%)
Lowest
USD 40,00 (+177,97%)
Analyst
Recommendation
Action
Price target
Projected
Date
Vamil Divan
Guggenheim
Buy
Reiterated
USD 47,00
+226,6%
10/01/2026
David Nierengarten
Wedbush
Buy
Maintained
USD 47,00
+226,6%
10/01/2026
Arthur He CFA
H.C. Wainwright
Buy
Maintained
USD 55,00
+282,2%
10/01/2026
Matt Phipps
William Blair
Buy
Reiterated
-
-
09/30/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
USD 42,00
+191,9%
09/30/2026
Kaveri Pohlman
Clear Street
Buy
Reiterated
USD 48,00
+233,6%
09/04/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
USD 40,00
+178%
08/13/2026
Akash Tewari
Jefferies
Buy
Maintained
USD 48,00
+233,6%
08/11/2026
Laura Chico
Wedbush
Buy
Maintained
USD 47,00
+226,6%
08/11/2026
Julian Harrison
BTIG
Buy
Maintained
USD 77,00
+435,1%
08/10/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
08/10/2026
Michael Yee
UBS
Buy
Initiated
USD 45,00
+212,7%
06/15/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
22,01 m
28,54 m
36,05 m
50,06 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,39 m
6,44 m
7,39 m
8,85 m
Operating expense
27,40 m
34,98 m
43,44 m
58,92 m
Total operating expenses
27,40 m
34,98 m
43,44 m
58,92 m
Operating income
-27,40 m
-34,98 m
-43,44 m
-58,92 m
Other non operating income
-28,00 k
20,00 k
-9,00 k
-62,00 k
EBT including unusual items
-25,18 m
-31,87 m
-40,35 m
-55,75 m
EBT excluding unusual items
-25,18 m
-31,87 m
-40,35 m
-55,75 m
Income tax expense
-
58,00 k
16,00 k
15,00 k
Effective tax rate
-
-0,18%
-0,04%
-0,03%
Other operating expenses
-
-
-
-
Net income
-25,18 m
-31,93 m
-40,37 m
-55,76 m
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-0,76
Interest and investment income
2,25 m
3,08 m
3,10 m
3,23 m
Interest expense
-
-
-
-
Net interest expenses
2,25 m
3,08 m
3,10 m
3,23 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-27,39 m
-34,97 m
-43,44 m
-58,91 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme